Results 151 to 160 of about 38,540 (306)

Targeting of peripheral blood T lymphocytes [PDF]

, 1996
Bolhuis, R.L.H. (Reinder), Gratama, J.W. (Jan-Willem), Hoogenboom, L.C.A.   +2 more
core   +1 more source

Orthotopic Esophageal Cancer Xenograft Model in Immunosuppressed Microminipigs for Near‐Infrared Fluorescence Endoscopy

Cancer Science, EarlyView.
We report the first successful orthotopic engraftment of human esophageal squamous cell carcinoma in immunosuppressed microminipigs and demonstrate high‐contrast near‐infrared fluorescence endoscopic detection using EGFR‐targeted cetuximab. This large‐animal model bridges preclinical imaging research and future clinical translation in esophageal cancer.
Takanori Miyake, Yutaka Kawano, Takanori Kashihara, Masaki Takasu, Kentaroh Takagaki, Shota Fujimoto, Tomoyuki Kawaguchi, Kaizo Kagemoto, Yoshifumi Kida, Koichi Okamoto, Masahiro Sogabe, Naoki Muguruma, Koichi Tsuneyama, Yasushi Sato, Tetsuji Takayama   +14 more
wiley   +1 more source

Elranatamab in Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Emerging Perspectives

European Journal of Haematology, EarlyView.
ABSTRACT Relapsed and refractory multiple myeloma (RRMM) remains associated with poor outcomes, particularly in patients exposed or refractory to proteasome inhibitors, immunomodulatory agents, and anti‐CD38 monoclonal antibodies. Targeting B‐cell maturation antigen (BCMA) has emerged as an effective therapeutic strategy, prompting the development of ...
Maria Eugenia Alvaro, Enrica Antonia Martino, Santino Caserta, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Ph‐Negative Acute Lymphoblastic Leukemia in the Older Adults: Biology, Therapeutic Strategies and Unmet Needs

European Journal of Haematology, EarlyView.
ABSTRACT Acute lymphoblastic leukaemia (ALL) in older adults represents a growing clinical challenge, driven by an ageing population, adverse disease biology, and reduced tolerance to intensive chemotherapy. Although pediatric‐inspired regimens have improved outcomes in younger adults with Philadelphia chromosome (Ph)‐negative ALL, survival in older ...
Antonella Bruzzese, Ernesto Vigna, Enrica Antonia Martino, Santino Caserta, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Marco Fiorillo, Nicola Amodio, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Incidence and Survival of Hemophagocytic Lymphohistiocytosis Over Two Decades: A Population‐Based Study

European Journal of Haematology, EarlyView.
ABSTRACT Adult hemophagocytic lymphohistiocytosis (HLH) is a rare, life‐threatening syndrome triggered by various conditions. A nationwide study of the incidence and outcomes of HLH in Denmark over 23 years (2000–2023) was performed. Adults (≥ 18 years) with HLH and triggering diseases were identified in the Danish National Patient Registry and/or the ...
Mads Okkels Birk Lorenzen, Martin Jensen, Rasmus Rask Kragh Jørgensen, Paw Jensen, Henrik Frederiksen, Dennis L. Hansen, Daniel El Fassi, Morten Nørgaard Andersen, Tarec Christoffer El‐Galaly   +8 more
wiley   +1 more source

CD3xCD20 bispecific antibodies in transformed Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. [PDF]

Hemasphere
Brocard M, Roos-Weil D, Kanagaratnam L, Hueso T, Bussot L, Papoular B, Tomowiak C, Chevreux S, Crochet G, Vaugeois T, Toussaint E, Ferrero S, Kyriakou C, Quinquenel A, Kapoor P, Durot E.   +15 more
europepmc   +1 more source

Loncastuximab Tesirine in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: Evidence and Practical Guidance From Italian Clinical Experience

European Journal of Haematology, EarlyView.
ABSTRACT Patients with relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) who progress to the third‐line setting face a lack of standardized treatment, despite the presence of multiple available therapies. In this context, antibody–drug conjugates represent a relatively new class of anticancer agents; among them, loncastuximab tesirine is ...
Francesca Bonello, Andrea Aroldi, Alessia Castellino, Lara Mannelli, Elia Boccellato, Serena Rosati, Luisa Verga, Umberto Vitolo   +7 more
wiley   +1 more source

Prognostic Impact of Chromosome 1q Gain/Amplification in Multiple Myeloma Treated With Daratumumab‐Based Regimens

European Journal of Haematology, EarlyView.
ABSTRACT Gain/amplification of chromosome arm 1q (+1q) is among the most frequent cytogenetic abnormalities (CAs) in multiple myeloma (MM), and a recognized marker of poor prognosis, now integrated into modern risk stratification systems. The advent of anti‐CD38 monoclonal antibodies, particularly daratumumab, has significantly improved outcomes ...
Emiliano Barbieri, Laura Arletti, Micol Quaresima, Elena Rivolti, Luca Braglia, Cecilia Fabiano, Adriana Maria Rita Alfano, Monia Rinaldini, Veronica Bizzarri, Chiara Cattani, Maria Marinelli, Barbara Gamberi   +11 more
wiley   +1 more source

Infections after bispecific antibodies in B-cell lymphomas. [PDF]

Blood Adv
Kim DH, Lee N, Koh Y, Jo HJ, Kang CK, Choe PG, Park WB, Lee CM, Byun JM, Kim NJ.   +9 more
europepmc   +1 more source

From Time‐Limited Therapy to Treatment‐Free Observation: The Evolving Role of MRD in CLL Management

European Journal of Haematology, EarlyView.
ABSTRACT The integration of measurable residual disease (MRD) into the management of chronic lymphocytic leukemia (CLL) has emerged as a major advance in risk stratification and trial design, particularly in the context of time‐limited, targeted regimens.
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Maria Eugenia Alvaro, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Mamdouh Skafi, Valter Gattei, Fortunato Morabito, Massimo Gentile   +13 more
wiley   +1 more source